
    
      Patients with breast cancer related lymphedema (clinical stage 0-2) will include in this
      study. Patients will take their demographic and clinical history and will evaluate with
      measurements of extremity volumes, body mass index, quality of life status and image studies
      (lymphoscintigraphy, USG, ICG or MRI) before and after the complete decongestive therapy
      (CDT). Outcome measurements such as limb volume, quality of life questionnaire and USG will
      repeat every 6,12,18, 24 months.

      Group 1: CDT Group 2: CDT + PO ketoprofen +Local ketoprofen gel Group 3: CDT + Local
      ketoprofen gel
    
  